Compare $MYGN vs $SPRY | Chartloom

Compare

$MYGN vs $SPRY

Myriad Genetics Inc · ARS Pharmaceuticals Inc

MYGN

Myriad Genetics Inc

SPRY

ARS Pharmaceuticals Inc

Compare $MYGN vs $SPRY

Comparing Myriad Genetics Inc and ARS Pharmaceuticals Inc

MYGNMyriad Genetics Inc

SPRYARS Pharmaceuticals Inc

MYGNMyriad Genetics Inc

Market cap

$407M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

0.50x

Rev growth (TTM)

-3.2%

YTD performance

-29.8%

52W performance

-43.6%

FCF yield

-3.5%

SPRYARS Pharmaceuticals Inc

Market cap

$420M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

2.81x

Rev growth (TTM)

4.1%

YTD performance

-63.2%

52W performance

-61.9%

FCF yield

-46.8%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

MYGN

SPRY

Detailed metrics comparison

MYGN

Myriad Genetics Inc

SPRY

ARS Pharmaceuticals Inc

Market Cap

MYGN$407M

SPRY$420M

Enterprise Value

MYGN$413M

SPRY$509M

Price

MYGN$4.31

SPRY$4.23

P/E Ratio

MYGNN/A

SPRYN/A

P/S Ratio

MYGN0.50x

SPRY3.59x

EV/Sales

MYGN0.51x

SPRY4.35x

EV/EBITDA

MYGN49.97x

SPRY0.00x

P/B Ratio

MYGN1.43x

SPRY32.35x

P/FCF Ratio

MYGNN/A

SPRYN/A

EV/FCF

MYGN-29.05x

SPRY-2.59x

PEG Ratio

MYGNN/A

SPRYN/A

Forward P/E (NTM)

MYGNN/A

SPRYN/A

Forward P/S (NTM)

MYGN0.50x

SPRY2.81x

Revenue (TTM)

MYGN$807M

SPRY$117M

Revenue Growth (YoY)

MYGN-3.2%

SPRY4.1%

Forward Rev Growth

MYGN5.6%

SPRY46.9%

Gross Margin (TTM)

MYGN68.8%

SPRY71.4%

Operating Margin (TTM)

MYGN0.0%

SPRY0.0%

EBITDA Margin (TTM)

MYGN-5.0%

SPRY-183.6%

Net Margin (TTM)

MYGN-14.0%

SPRY-184.2%

FCF Margin (TTM)

MYGN-1.8%

SPRY-168.1%

Net Income (TTM)

MYGN$-113M

SPRY$-215M

FCF (TTM)

MYGN$-14M

SPRY$-197M

EPS (TTM)

MYGN-$1.19

SPRY-$2.17

ROE (TTM)

MYGN-3259.0%

SPRY-25667.0%

ROA (TTM)

MYGN-1639.0%

SPRY-6963.0%

ROIC (TTM)

MYGN-2418.0%

SPRY-11943.0%

Cash

MYGN$115M

SPRY$8M

Debt

MYGN$121M

SPRY$97M

Net Cash/Debt

MYGN$-6M

SPRY$-89M

Current Ratio (TTM)

MYGN2.21x

SPRY3.48x

Quick Ratio (TTM)

MYGN1.72x

SPRY3.13x

Debt/Equity (TTM)

MYGN0.40x

SPRY7.73x

Debt/Assets (TTM)

MYGN0.0%

SPRY0.0%

Interest Coverage (TTM)

MYGNN/A

SPRYN/A

Net Debt/EBITDA (TTM)

MYGN0.00x

SPRY0.00x

Beta

MYGN1.68

SPRY0.92

52W Performance

MYGN-43.6%

SPRY-61.9%

YTD Performance

MYGN-29.8%

SPRY-63.2%

% from 52W High

MYGN-49.8%

SPRY-67.8%

% from 52W Low

MYGN57.3%

SPRY6.1%

Asset Turnover (TTM)

MYGN1.17x

SPRY0.38x

FCF Yield (TTM)

MYGN-3.5%

SPRY-46.8%

Earnings Yield (TTM)

MYGN-27.7%

SPRY-51.3%

Dividend Yield (TTM)

MYGNN/A

SPRYN/A

Rule of 40

MYGN-4.9

SPRY-164.1

EV/GP/RG

MYGN1.67

SPRY0.16

Ticker research

View MYGN research View SPRY research

Metric	MYGN Myriad Genetics Inc	SPRY ARS Pharmaceuticals Inc
Market & Valuation
Market Cap	$407M	$420M
Enterprise Value	$413M	$509M
Price	$4.31	$4.23
P/E Ratio	N/A	N/A
P/S Ratio	0.50x	3.59x
EV/Sales	0.51x	4.35x
EV/EBITDA	49.97x	0.00x
P/B Ratio	1.43x	32.35x
P/FCF Ratio	N/A	N/A
EV/FCF	-29.05x	-2.59x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	0.50x	2.81x
Revenue & Growth
Revenue (TTM)	$807M	$117M
Revenue Growth (YoY)	-3.2%	4.1%
Forward Rev Growth	5.6%	46.9%
Profitability
Gross Margin (TTM)	68.8%	71.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-5.0%	-183.6%
Net Margin (TTM)	-14.0%	-184.2%
FCF Margin (TTM)	-1.8%	-168.1%
Net Income (TTM)	$-113M	$-215M
FCF (TTM)	$-14M	$-197M
EPS (TTM)	-$1.19	-$2.17
ROE (TTM)	-3259.0%	-25667.0%
ROA (TTM)	-1639.0%	-6963.0%
ROIC (TTM)	-2418.0%	-11943.0%
Financial Health
Cash	$115M	$8M
Debt	$121M	$97M
Net Cash/Debt	$-6M	$-89M
Current Ratio (TTM)	2.21x	3.48x
Quick Ratio (TTM)	1.72x	3.13x
Debt/Equity (TTM)	0.40x	7.73x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.68	0.92
52W Performance	-43.6%	-61.9%
YTD Performance	-29.8%	-63.2%
% from 52W High	-49.8%	-67.8%
% from 52W Low	57.3%	6.1%
Efficiency & Yields
Asset Turnover (TTM)	1.17x	0.38x
FCF Yield (TTM)	-3.5%	-46.8%
Earnings Yield (TTM)	-27.7%	-51.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-4.9	-164.1
EV/GP/RG	1.67	0.16
Ticker research	View MYGN research	View SPRY research

Valuation

P/S Ratio

MYGN

0.50x

SPRY

3.59x

EV/FCF

MYGN

-29.05x

SPRY

-2.59x

Growth & revenue

Revenue Growth TTM

SPRY

4.1%

MYGN

-3.2%

Forward Revenue Growth

SPRY

46.9%

MYGN

5.6%

Profitability & performance

Gross Margin

SPRY

71.4%

MYGN

68.8%

ROE

MYGN

-3259.0%

SPRY

-25667.0%

FCF Yield %

MYGN

-3.5%

SPRY

-46.8%

52-Week Performance

MYGN

-43.6%

SPRY

-61.9%

Detailed metrics comparison

MYGN

Myriad Genetics Inc

SPRY

ARS Pharmaceuticals Inc

Market Cap

MYGN$407M

SPRY$420M

Enterprise Value

MYGN$413M

SPRY$509M

Price

MYGN$4.31

SPRY$4.23

P/E Ratio

MYGNN/A

SPRYN/A

P/S Ratio

MYGN0.50x

SPRY3.59x

EV/Sales

MYGN0.51x

SPRY4.35x

EV/EBITDA

MYGN49.97x

SPRY0.00x

P/B Ratio

MYGN1.43x

SPRY32.35x

P/FCF Ratio

MYGNN/A

SPRYN/A

EV/FCF

MYGN-29.05x

SPRY-2.59x

PEG Ratio

MYGNN/A

SPRYN/A

Forward P/E (NTM)

MYGNN/A

SPRYN/A

Forward P/S (NTM)

MYGN0.50x

SPRY2.81x

Revenue (TTM)

MYGN$807M

SPRY$117M

Revenue Growth (YoY)

MYGN-3.2%

SPRY4.1%

Forward Rev Growth

MYGN5.6%

SPRY46.9%

Gross Margin (TTM)

MYGN68.8%

SPRY71.4%

Operating Margin (TTM)

MYGN0.0%

SPRY0.0%

EBITDA Margin (TTM)

MYGN-5.0%

SPRY-183.6%

Net Margin (TTM)

MYGN-14.0%

SPRY-184.2%

FCF Margin (TTM)

MYGN-1.8%

SPRY-168.1%

Net Income (TTM)

MYGN$-113M

SPRY$-215M

FCF (TTM)

MYGN$-14M

SPRY$-197M

EPS (TTM)

MYGN-$1.19

SPRY-$2.17

ROE (TTM)

MYGN-3259.0%

SPRY-25667.0%

ROA (TTM)

MYGN-1639.0%

SPRY-6963.0%

ROIC (TTM)

MYGN-2418.0%

SPRY-11943.0%

Cash

MYGN$115M

SPRY$8M

Debt

MYGN$121M

SPRY$97M

Net Cash/Debt

MYGN$-6M

SPRY$-89M

Current Ratio (TTM)

MYGN2.21x

SPRY3.48x

Quick Ratio (TTM)

MYGN1.72x

SPRY3.13x

Debt/Equity (TTM)

MYGN0.40x

SPRY7.73x

Debt/Assets (TTM)

MYGN0.0%

SPRY0.0%

Interest Coverage (TTM)

MYGNN/A

SPRYN/A

Net Debt/EBITDA (TTM)

MYGN0.00x

SPRY0.00x

Beta

MYGN1.68

SPRY0.92

52W Performance

MYGN-43.6%

SPRY-61.9%

YTD Performance

MYGN-29.8%

SPRY-63.2%

% from 52W High

MYGN-49.8%

SPRY-67.8%

% from 52W Low

MYGN57.3%

SPRY6.1%

Asset Turnover (TTM)

MYGN1.17x

SPRY0.38x

FCF Yield (TTM)

MYGN-3.5%

SPRY-46.8%

Earnings Yield (TTM)

MYGN-27.7%

SPRY-51.3%

Dividend Yield (TTM)

MYGNN/A

SPRYN/A

Rule of 40

MYGN-4.9

SPRY-164.1

EV/GP/RG

MYGN1.67

SPRY0.16

Ticker research

View MYGN research View SPRY research

Metric	MYGN Myriad Genetics Inc	SPRY ARS Pharmaceuticals Inc
Market & Valuation
Market Cap	$407M	$420M
Enterprise Value	$413M	$509M
Price	$4.31	$4.23
P/E Ratio	N/A	N/A
P/S Ratio	0.50x	3.59x
EV/Sales	0.51x	4.35x
EV/EBITDA	49.97x	0.00x
P/B Ratio	1.43x	32.35x
P/FCF Ratio	N/A	N/A
EV/FCF	-29.05x	-2.59x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	0.50x	2.81x
Revenue & Growth
Revenue (TTM)	$807M	$117M
Revenue Growth (YoY)	-3.2%	4.1%
Forward Rev Growth	5.6%	46.9%
Profitability
Gross Margin (TTM)	68.8%	71.4%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	-5.0%	-183.6%
Net Margin (TTM)	-14.0%	-184.2%
FCF Margin (TTM)	-1.8%	-168.1%
Net Income (TTM)	$-113M	$-215M
FCF (TTM)	$-14M	$-197M
EPS (TTM)	-$1.19	-$2.17
ROE (TTM)	-3259.0%	-25667.0%
ROA (TTM)	-1639.0%	-6963.0%
ROIC (TTM)	-2418.0%	-11943.0%
Financial Health
Cash	$115M	$8M
Debt	$121M	$97M
Net Cash/Debt	$-6M	$-89M
Current Ratio (TTM)	2.21x	3.48x
Quick Ratio (TTM)	1.72x	3.13x
Debt/Equity (TTM)	0.40x	7.73x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	1.68	0.92
52W Performance	-43.6%	-61.9%
YTD Performance	-29.8%	-63.2%
% from 52W High	-49.8%	-67.8%
% from 52W Low	57.3%	6.1%
Efficiency & Yields
Asset Turnover (TTM)	1.17x	0.38x
FCF Yield (TTM)	-3.5%	-46.8%
Earnings Yield (TTM)	-27.7%	-51.3%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	-4.9	-164.1
EV/GP/RG	1.67	0.16
Ticker research	View MYGN research	View SPRY research